Results 171 to 180 of about 153,475 (357)

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
Annemieke M. Peters van Ton   +4 more
wiley   +1 more source

Relation between metabolic syndrome and thyroid volume and nodular thyroid diseases in elderly adults with metabolic syndrome

open access: yesThe Egyptian Journal of Internal Medicine
Background One of the most common clinical thyroid related disorders is thyroid nodules (TNs). The metabolic syndrome (Mets) frequency rise significantly with age, TNs are prevalent in older adults, and their incidence increases with age.
Fady Nagy L. Mehany   +4 more
doaj   +1 more source

Malignant carcinoma and skin melanoma neoplasms concomitantly in the thyroid [PDF]

open access: gold, 2021
Ali Al‐Harake   +8 more
openalex   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

X‐ray controlled release strategy in cancer therapy

open access: yesBMEMat, EarlyView.
A comprehensive review on the design principles and current strategies of X‐ray stimulated release systems in cancer therapy, focusing on the X‐ray responsive functional groups and materials as well as discussing the advantages and current challenges of X‐ray controlled release systems in cancer therapy.
Yiling Ruan   +5 more
wiley   +1 more source

The Value of Relative Size in the Ultrasound Diagnosis of Follicular Thyroid Neoplasm. [PDF]

open access: yesInt J Gen Med, 2021
Zhang S   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy